Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: Experience from australian stroke center

Stroke

Volumn 44, Issue 8, 2013, Pages 2269-2274

  Tan Tanny, Sharman P ^a   Busija, Lucy ^a   Liew, Danny ^a   Teo, Sarah ^a   Davis, Stephen M ^a   Yan, Bernard ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

cost benefit analysis; stroke; stroke, acute; thrombolytic therapy; tissue type plasminogen activator

Indexed keywords

PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; AUSTRALIA; BLOOD CLOT LYSIS; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HOSPITAL COST; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; TIME TO TREATMENT;

COST-BENEFIT ANALYSIS; STROKE; STROKE, ACUTE; THROMBOLYTIC THERAPY; TISSUE-TYPE PLASMINOGEN ACTIVATOR;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; COST-BENEFIT ANALYSIS; FEMALE; FIBRINOLYTIC AGENTS; HOSPITAL COSTS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VICTORIA;

EID: 84880765729     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001295     Document Type: Article

References (29)

1. Dewey HM, Thrift AG, Mihalopoulos C, Carter R, Macdonell RA, McNeil JJ, et al. Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2001;32:2409-2416. (Pubitemid 32958558)
2. Cox AM, McKevitt C, Rudd AG, Wolfe CD. Socioeconomic status and stroke. Lancet Neurol. 2006;5:181-188. (Pubitemid 43107853)
3. Mathers C, Vo s T, Stevenson C. The Burden of Disease and Injury in Australia. Summary Report. Canberra: Australian Institute of Health and Welfare; 1999.
4. Cadilhac D, Thrift AGT, Dewey HMD, Carter RC. Investing in Stroke: What Are the Potential Cost Offsets From the Strokesafe Program. Final Report, Melbourne, Victoria: National Stroke Research Institute; 2005.
5. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
6. Hajjar K, Kerr DM, Lees KR. Thrombolysis for acute ischemic stroke. J Vasc Surg. 2011;54:901-907.
7. Minnerup J, Wersching H, Ringelstein EB, Schilling M, Schäbitz WR, Wellmann J, et al. Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time. Stroke. 2011;42:2838-2843.
8. Lansberg MG, Bluhmki E, Thijs VN. Effcacy and safety of tissue plas-minogen activator 3 to 4.5 hours after acute ischemic stroke: a meta-analysis. Stroke. 2009;40:2438-2441.
9. Shobha N, Buchan AM, Hill MD; Canadian Alteplase for Stroke Effectiveness Study (CASES). Thrombolysis at 3-4.5 hours after acute ischemic stroke onset-evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Cerebrovasc Dis. 2011;31:223-228.
10. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
11. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al. The benefts and harms of intravenous thrombolysis with recombi-nant tissue plasminogen activator within 6 h of acute ischemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379(9834):2352-2363.
12. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251. (Pubitemid 28470336)
13. Tung CE, Win SS, Lansberg MG. Cost-effectiveness of tissue-type plas-minogen activator in the 3-to 4.5-hour time window for acute ischemic stroke. Stroke. 2011;42:2257-2262.
14. Jung KT, Shin DW, Lee KJ, Oh M. Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review. J Clin Neurol. 2010;6:117-126.
15. Yip TR, Demaerschalk BM. Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada. Stroke. 2007;38:1952-1955. (Pubitemid 46847275)
16. Demaerschalk BM, Yip TR. Economic beneft of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke. 2005;36:2500-2503. (Pubitemid 41566988)
17. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50:883-890. (Pubitemid 28212810)
18. Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med. 2013;61:46-55.
19. Mihalopoulos C, Cadilhac DA, Moodie ML, Dewey HM, Thrift AG, Donnan GA, et al. Development and application of Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS): an Australian economic model for stroke. Int J Technol Assess Health Care. 2005;21:499-505. (Pubitemid 41642843)
20. Lilford RJ, Pauker SG, Braunholtz DA, Chard J. Decision analysis and the implementation of research fndings. BMJ. 1998;317:405-409.
21. Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J, et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol. 1999;52:259-271. (Pubitemid 29148438)
22. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-500. (Pubitemid 30398806)
23. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
24. Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009;12:80-87.
25. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, et al. A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. Health Technol Assess. 2002;6:1-112.
26. Sinclair SE, Frighetto L, Loewen PS, Sunderji R, Teal P, Fagan SC, et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics. 2001;19:927-936. (Pubitemid 32937943)
27. Johnston SC. The economic case for new stroke thrombolytics. Stroke. 2010;41(suppl 10):S59-S62.
28. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke. 2004;35:1490-1497. (Pubitemid 38697481)
29. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics. 2006;24:1043-1053. (Pubitemid 44683362)